DBV Technologies (NASDAQ:DBVT) Upgraded at Zacks Research

Zacks Research upgraded shares of DBV Technologies (NASDAQ:DBVT) from a strong sell rating to a hold rating in a research report report published on Monday morning,Zacks.com reports.

A number of other brokerages also recently issued reports on DBVT. JMP Securities restated a “market outperform” rating and set a $21.00 price target on shares of DBV Technologies in a report on Thursday, June 26th. Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Friday, July 18th. Finally, Lifesci Capital upgraded shares of DBV Technologies to a “strong-buy” rating in a report on Thursday, June 26th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, DBV Technologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.75.

DBV Technologies Price Performance

DBVT opened at $10.07 on Monday. The company’s 50 day simple moving average is $9.56 and its two-hundred day simple moving average is $8.95. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $12.78. The firm has a market capitalization of $275.92 million, a price-to-earnings ratio of -2.11 and a beta of -0.45.

DBV Technologies (NASDAQ:DBVT) last announced its quarterly earnings results on Tuesday, July 29th. The company reported ($1.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($1.34). The firm had revenue of $1.74 million for the quarter, compared to analyst estimates of $0.64 million. DBV Technologies had a negative return on equity of 287.15% and a negative net margin of 3,220.49%. On average, equities analysts anticipate that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

Several institutional investors have recently modified their holdings of DBVT. Nan Fung Trinity HK Ltd. acquired a new position in shares of DBV Technologies in the second quarter worth $340,000. Vivo Capital LLC purchased a new stake in shares of DBV Technologies during the 2nd quarter worth $9,659,000. MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies during the 2nd quarter worth $9,649,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of DBV Technologies during the 2nd quarter worth $9,659,000. Finally, Octagon Capital Advisors LP purchased a new stake in shares of DBV Technologies during the 2nd quarter worth $9,315,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.